Michael Mortensen
Chief Operating Officer chez BONESUPPORT HOLDING AB
Fortune : 828 085 $ au 31/03/2024
Profil
Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate from the University of Copenhagen, and an MBA from AVT Business School A.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BONESUPPORT HOLDING AB
0,06% | 05/03/2024 | 38 835 ( 0,06% ) | 828 085 $ | 31/03/2024 |
Postes actifs de Michael Mortensen
| Sociétés | Poste | Début |
|---|---|---|
| BONESUPPORT HOLDING AB | Chief Operating Officer | 01/12/2021 |
Nanovi Radiotherapy A/S
 Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Corporate Officer/Principal | - |
Formation de Michael Mortensen
| Technical University of Denmark | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
| AVT Business School A/S | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BONESUPPORT HOLDING AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
